Chronic Kidney Disease: Effects on the Cardiovascular System

Accelerated cardiovascular disease is a frequent complication of renal disease. Chronic kidney disease promotes hypertension and dyslipidemia, which in turn can contribute to the progression of renal failure. Furthermore, diabetic nephropathy is the leading cause of renal failure in developed countries. Together, hypertension, dyslipidemia, and diabetes are major risk factors for the development of endothelial dysfunction and progression of atherosclerosis. Inflammatory mediators are often elevated and the renin-angiotensin system is frequently activated in chronic kidney disease, which likely contributes through enhanced production of reactive oxygen species to the accelerated atherosclerosis observed in chronic kidney disease. Promoters of calcification are increased and inhibitors of calcification are reduced, which favors metastatic vascular calcification, an important participant in vascular injury associated with end-stage renal disease. Accelerated atherosclerosis will then lead to increased prevalence of coronary artery disease, heart failure, stroke, and peripheral arterial disease. Consequently, subjects with chronic renal failure are exposed to increased morbidity and mortality as a result of cardiovascular events. Prevention and treatment of cardiovascular disease are major considerations in the management of individuals with chronic kidney disease.

[1]  M. Cheitlin,et al.  Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2008 .

[2]  J. Griffith,et al.  Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[3]  K. Homma,et al.  Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[4]  W. März,et al.  Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.

[5]  M. Shlipak,et al.  Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.

[6]  F. Locatelli,et al.  Anemia and cardiovascular risk: the lesson of the CREATE Trial. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  R. Jofré,et al.  Inflammatory syndrome in patients on hemodialysis. , 2006, Journal of the American Society of Nephrology : JASN.

[8]  J. Loscalzo,et al.  Vascular Calcification: Pathobiological Mechanisms and Clinical Implications , 2006, Circulation research.

[9]  C. Wanner,et al.  Cross-talk between the kidney and the cardiovascular system. , 2006, Journal of the American Society of Nephrology : JASN.

[10]  C. Stehouwer,et al.  Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  T. Imaizumi,et al.  Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[12]  S. Solomon,et al.  Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial , 2006, Circulation.

[13]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[14]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  J. Floege,et al.  Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon , 2006, Hypertension.

[16]  R. Trevisan,et al.  Lipids and renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[17]  S. Cummings,et al.  Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. , 2005, Journal of the American Society of Nephrology : JASN.

[18]  I. Jaussent,et al.  Plasma osteoprotegerin is associated with mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  C. Zoccali,et al.  The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  L. Bouter,et al.  Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. , 2006, Journal of the American Society of Nephrology : JASN.

[21]  P. Chaves,et al.  Kidney function as a predictor of noncardiovascular mortality. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  W. Qunibi Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[23]  M. Pfeffer,et al.  Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.

[24]  F. Kronenberg,et al.  Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  C. Zoccali,et al.  Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  Carmine Zoccali,et al.  Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. , 2005, Journal of the American Society of Nephrology : JASN.

[27]  W. C. O'Neill,et al.  Reduced plasma pyrophosphate levels in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  K. Hruska,et al.  Bone Morphogenetic Proteins in Vascular Calcification , 2005, Circulation research.

[29]  N. Chen,et al.  Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). , 2005, Kidney international.

[30]  P. Stenvinkel,et al.  Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. , 2005, Kidney international.

[31]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[32]  Xiaoqiang Yao,et al.  Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. , 2005, The Journal of clinical investigation.

[33]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[34]  L. Fried,et al.  Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults , 2005, Annals of Internal Medicine.

[35]  R. Terkeltaub,et al.  Chondrogenesis Mediated by PPi Depletion Promotes Spontaneous Aortic Calcification in NPP1−/− Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[36]  J. Passauer,et al.  Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. , 2005, Journal of the American Society of Nephrology : JASN.

[37]  M. Safar,et al.  Stiffness of Capacitive and Conduit Arteries: Prognostic Significance for End-Stage Renal Disease Patients , 2005, Hypertension.

[38]  E. Schiffrin,et al.  p47phox Associates With the Cytoskeleton Through Cortactin in Human Vascular Smooth Muscle Cells: Role in NAD(P)H Oxidase Regulation by Angiotensin II , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[39]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[40]  V. Andreucci,et al.  Coronary artery calcification in patients with CRF not undergoing dialysis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[42]  H. Gerstein,et al.  Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. , 2004, Kidney international. Supplement.

[43]  M. Pfeffer,et al.  Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. , 2004, Kidney international. Supplement.

[44]  L. Schurgers,et al.  Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. , 2004, Journal of the American Society of Nephrology : JASN.

[45]  L. Bouter,et al.  Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the Hoorn Study. , 2004, Kidney international. Supplement.

[46]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[47]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[48]  E. Schiffrin,et al.  Reactive oxygen species in vascular biology: implications in hypertension , 2004, Histochemistry and Cell Biology.

[49]  B. Brenner,et al.  Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.

[50]  E. Schiffrin,et al.  From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. , 2004, American journal of physiology. Heart and circulatory physiology.

[51]  K. Borch-Johnsen,et al.  Preventive cardiology: abstractVery low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes☆ , 2004 .

[52]  P. Vallance,et al.  Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[53]  P. Blankestijn,et al.  Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. , 2004, Kidney international.

[54]  J. Cooke Asymmetrical Dimethylarginine: The Über Marker? , 2004, Circulation.

[55]  R. Terkeltaub,et al.  Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. , 2004, The American journal of pathology.

[56]  J. Eiserich,et al.  The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.

[57]  H. Parving,et al.  Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. , 2004, Diabetes care.

[58]  S. Saito,et al.  Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography , 2004, Thrombosis and Haemostasis.

[59]  C. Zoccali,et al.  Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[60]  D. Tsikas,et al.  Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.

[61]  Ernesto L. Schiffrin,et al.  Endothelial dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.

[62]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[63]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[64]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[65]  K. Nitta,et al.  The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[66]  P. Stenvinkel,et al.  Associations between circulating inflammatory markers and residual renal function in CRF patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[67]  P. Stenvinkel,et al.  A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. , 2003, Kidney international. Supplement.

[68]  C. Wanner,et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.

[69]  D. Grobbee,et al.  Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.

[70]  D. Kereiakes,et al.  Endothelial dysfunction. , 2003, Circulation.

[71]  N. Hollenberg,et al.  Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. , 2003, Kidney international.

[72]  N. Vaziri,et al.  Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. , 2003, Kidney international.

[73]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[74]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[75]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[76]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[77]  B. Dahlof,et al.  Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol☆ , 2002 .

[78]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[79]  K. Boström,et al.  Matrix GLA Protein, a Regulatory Protein for Bone Morphogenetic Protein-2* , 2002, The Journal of Biological Chemistry.

[80]  Will F. Figueira,et al.  Discovery of a High Molecular Weight Complex of Calcium, Phosphate, Fetuin, and Matrix γ-Carboxyglutamic Acid Protein in the Serum of Etidronate-treated Rats* , 2002, The Journal of Biological Chemistry.

[81]  M. Rathaus,et al.  Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. , 2002, Kidney international.

[82]  C. Zoccali,et al.  Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[83]  N. Vaziri,et al.  Enhanced Nitric Oxide Inactivation and Protein Nitration by Reactive Oxygen Species in Renal Insufficiency , 2002, Hypertension.

[84]  D. Fliser,et al.  Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[85]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[86]  E. Ritz,et al.  Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. , 2001, Journal of the American Society of Nephrology : JASN.

[87]  J. Blacher,et al.  Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease , 2001, Hypertension.

[88]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[89]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[90]  D. Fliser,et al.  ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[91]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[92]  F. Parhami,et al.  Leptin Enhances the Calcification of Vascular Cells: Artery Wall as a Target of Leptin , 2001, Circulation research.

[93]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[94]  C. Wanner,et al.  Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[95]  A. Zanchetti,et al.  Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.

[96]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[97]  P. Stenvinkel,et al.  Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[98]  D. Levy,et al.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.

[99]  Coleman Tg,et al.  Quantitative analysis of the pathophysiology of hypertension. 1969. , 1999 .

[100]  R. Foley,et al.  Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease and cardiac failure. Semin Dial 2003 , 2022 .

[101]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[102]  M. Hijmering,et al.  Nitric oxide production is reduced in patients with chronic renal failure. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[103]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[104]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[105]  A. Fitzgerald,et al.  Microalbuminuria and coronary heart disease in NIDDM: an incidence study. , 1998, Diabetes.

[106]  A. Collins,et al.  Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.

[107]  E. Ritz,et al.  Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.

[108]  N. Vaziri,et al.  Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. , 1998, Kidney international.

[109]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[110]  J. Skepper,et al.  Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[111]  B. Kasiske,et al.  Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. , 1997, Kidney international. Supplement.

[112]  A. Skene,et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.

[113]  F. Fabbian,et al.  Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[114]  R. Behringer,et al.  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.

[115]  M. Budisavljevic,et al.  Calciphylaxis in chronic renal failure. , 1996, Journal of the American Society of Nephrology : JASN.

[116]  Howard C. Tenenbaum,et al.  Fetuin/α2-HS Glycoprotein Is a Transforming Growth Factor-β Type II Receptor Mimic and Cytokine Antagonist* , 1996, The Journal of Biological Chemistry.

[117]  David C. Murray,et al.  Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. , 1996, Kidney international.

[118]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[119]  A. Schwarz,et al.  Severe calciphylaxis in a renal patient on long-term oral anticoagulant therapy. , 1996, American journal of nephrology.

[120]  G. Burg,et al.  Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. , 1995, Journal of the American Academy of Dermatology.

[121]  R. Zatz,et al.  Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. , 1995, Journal of the American Society of Nephrology : JASN.

[122]  David C. Murray,et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.

[123]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.

[124]  P. Weissberg,et al.  High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[125]  R. Converse,et al.  Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.

[126]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[127]  M. Blaufox,et al.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. , 1989, Hypertension.

[128]  W. Kannel,et al.  The prognostic significance of proteinuria: the Framingham study. , 1984, American heart journal.

[129]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[130]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[131]  D. J. Patel,et al.  The Elastic Symmetry of Arterial Segments in Dogs , 1969, Circulation research.

[132]  T. G. Coleman,et al.  Quantitative analysis of the pathophysiology of hypertension. , 1969, Circulation research.